Daily Coffee Intake Inhibits Pancreatic Beta Cell Damage and Nonalcoholic Steatohepatitis in a Mouse Model of Spontaneous Metabolic Syndrome, Tsumura-Suzuki Obese Diabetic Mice

Metab Syndr Relat Disord. 2017 May;15(4):170-177. doi: 10.1089/met.2016.0114. Epub 2017 Mar 30.

Abstract

Background: Metabolic syndrome is one of the most important health issues worldwide. Obesity causes insulin resistance, hyperlipidemia, diabetes, and various diseases throughout the body. The liver phenotype, which is called nonalcoholic steatohepatitis (NASH), frequently progresses to hepatocellular carcinoma. We recently established a new animal model, Tsumura-Suzuki obese diabetic (TSOD) mice, which spontaneously exhibit obesity, diabetes, hyperlipidemia, and NASH with liver nodules.

Methods: We examined the effects of coffee intake on various conditions of the metabolic syndrome using TSOD mice. The daily volume of coffee administered was limited so that it reflected the appropriate quantities consumed in humans. To clarify the effects of the specific components, animals were divided into two coffee-intake groups that included with and without caffeine.

Results: Coffee intake did not significantly affect obesity and hyperlipidemia in TSOD mice. In contrast, coffee intake caused various degrees of improvement in the pancreatic beta cell damage and steatohepatitis with liver carcinogenesis. Most of the effects were believed to be caused by a synergistic effect of caffeine with other components such as polyphenols. However, the antifibrotic effects of coffee appeared to be due to the polyphenols rather than the caffeine.

Conclusions: A daily habit of drinking coffee could possibly play a role in the prevention of metabolic syndrome.

Keywords: animal model; beta cell failure; coffee intake; hepatocellular carcinoma; nonalcoholic steatohepatitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging
  • Animals
  • Caffeine / therapeutic use
  • Coffee*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / pathology
  • Diabetes Mellitus, Type 2 / prevention & control
  • Hyperlipidemias / blood
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / pathology
  • Intra-Abdominal Fat / drug effects
  • Intra-Abdominal Fat / metabolism
  • Liver / pathology
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / prevention & control
  • Liver Neoplasms / epidemiology
  • Liver Neoplasms / prevention & control
  • Male
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / drug therapy*
  • Mice
  • Mice, Obese
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / pathology
  • Non-alcoholic Fatty Liver Disease / prevention & control*
  • Phosphodiesterase Inhibitors / therapeutic use

Substances

  • Coffee
  • Phosphodiesterase Inhibitors
  • Caffeine